Deal Terminations Not The End Of The Road For Licensed Drugs
Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
You may also be interested in...
In earlier development phases, most of the therapeutic classes with higher approval rates tend on average to have the larger up-front alliance payments. But in Phase III, licensees are paying top dollar for candidates in areas with the lowest likelihoods of approval.
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.